Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
NCT06468215Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2024
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of avatrombopag, medroxyprogesterone acetate and megestrol in endometrial cancer (EC) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Time Required for Complete Remission for the First Time at 5 years. Started Jun 2024; status: recruiting.
02
Drugs
avatrombopagmedroxyprogesterone acetatemegestrol
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06468215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468215.